ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > accreditation of SARS COV2 immunoassay

<< Previous

Bullboard Posts

Next >>

Comment by Thenorth1990on Dec 21, 2020 4:53pm

108 Views

Post# 32155023

RE:accreditation of SARS COV2 immunoassay

May be you have seen this already, but in the below list there is no mention of Promis or BC neuro . does that mean , they havent even applied for this with health Canada/FDA?
As per their press release it should have been ready by Summer, expected revenues by q4 and they just went completely silent. I understand Serology test is not their priority, but some revenue helps and if they announce Serology test is no more in pipeline, not sure what happens.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?